These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 34315832)
1. Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. Chandra J; Parakh N; Sidharth ; Singh N; Sharma S; Goel M; Pemde H Indian Pediatr; 2021 Jul; 58(7):611-616. PubMed ID: 34315832 [TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India. Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of thalidomide for various genotypes of beta thalassemia. Yang WJ; Kang QP; Zhou Q; Lin T; Gong XM; Huang CJ; Dou M; Lin Y BMC Med Genomics; 2024 Jul; 17(1):191. PubMed ID: 39026312 [TBL] [Abstract][Full Text] [Related]
4. Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life. Bhattacharjee S; Ghosh S; Shaw J; Bhattacharjee S; Bhattacharyya M Hemoglobin; 2024 May; 48(3):161-168. PubMed ID: 39092801 [TBL] [Abstract][Full Text] [Related]
5. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients. Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study. Li X; Hu S; Liu Y; Huang J; Hong W; Xu L; Xu H; Fang J Front Pharmacol; 2021; 12():722502. PubMed ID: 34456732 [No Abstract] [Full Text] [Related]
7. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial. Chen JM; Zhu WJ; Liu J; Wang GZ; Chen XQ; Tan Y; Xu WW; Qu LW; Li JY; Yang HJ; Huang L; Cai N; Wang WD; Huang K; Xu JQ; Li GH; He S; Luo TY; Huang Y; Liu SH; Wu WQ; Lu QY; Zhou MG; Chen SY; Li RL; Hu ML; Huang Y; Wei JH; Li JM; Chen SJ; Zhou GB Signal Transduct Target Ther; 2021 Nov; 6(1):405. PubMed ID: 34795208 [TBL] [Abstract][Full Text] [Related]
8. Promising Response to Thalidomide in Symptomatic β-Thalassemia. Yassin AK Indian J Hematol Blood Transfus; 2020 Apr; 36(2):337-341. PubMed ID: 32425386 [TBL] [Abstract][Full Text] [Related]
9. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study. Ali Z; Ismail M; Rehman IU; Rani GF; Ali M; Khan MTM Sci Rep; 2023 Aug; 13(1):13592. PubMed ID: 37604857 [TBL] [Abstract][Full Text] [Related]
10. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major. Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819 [TBL] [Abstract][Full Text] [Related]
11. Thalidomide for Patients with β-Thalassemia: A Multicenter Experience. Yang K; Wu Y; Zhou Y; Long B; Lu Q; Zhou T; Wang L; Geng Z; Yin X Mediterr J Hematol Infect Dis; 2020; 12(1):e2020021. PubMed ID: 32395210 [TBL] [Abstract][Full Text] [Related]
12. Investigating the Efficacy and Safety of Thalidomide for Treating Patients With Lu Y; Wei Z; Yang G; Lai Y; Liu R Front Pharmacol; 2021; 12():814302. PubMed ID: 35087410 [TBL] [Abstract][Full Text] [Related]
13. Thalidomide has a significant effect in patients with thalassemia intermedia. Li Y; Ren Q; Zhou Y; Li P; Lin W; Yin X Hematology; 2018 Jan; 23(1):50-54. PubMed ID: 28718348 [TBL] [Abstract][Full Text] [Related]
14. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience. Nag A; Radhakrishnan VS; Kumar J; Bhave S; Mishra DK; Nair R; Chandy M Indian J Hematol Blood Transfus; 2020 Apr; 36(2):399-402. PubMed ID: 32425398 [TBL] [Abstract][Full Text] [Related]
15. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study. Cappellini MD; Porter J; Origa R; Forni GL; Voskaridou E; Galactéros F; Taher AT; Arlet JB; Ribeil JA; Garbowski M; Graziadei G; Brouzes C; Semeraro M; Laadem A; Miteva D; Zou J; Sung V; Zinger T; Attie KM; Hermine O Haematologica; 2019 Mar; 104(3):477-484. PubMed ID: 30337358 [TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients. Bhattacharjee U; Khadwal A; Shafiq N; Lad D; Sharma P; Das R; Shukla P; Jain A; Prakash G; Malhotra P Indian J Hematol Blood Transfus; 2023 Apr; 39(2):266-275. PubMed ID: 36620489 [TBL] [Abstract][Full Text] [Related]
17. Acute Effects of Blood Transfusion on Insulin Sensitivity and Pancreatic β-Cell Function in Children with β-Thalassemia/Hemoglobin E Disease. Wankanit S; Chuansumrit A; Poomthavorn P; Khlairit P; Pongratanakul S; Mahachoklertwattana P J Clin Res Pediatr Endocrinol; 2018 Mar; 10(1):1-7. PubMed ID: 28739553 [TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Thalidomide and Hydroxyurea Combination in Beta Thalassemia Patients. Garg A; Patel K; Shah K; Trivedi D; Raj A; Yadav R; Shah S Indian J Hematol Blood Transfus; 2023 Jan; 39(1):85-89. PubMed ID: 36699430 [TBL] [Abstract][Full Text] [Related]
19. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Ren Q; Zhou YL; Wang L; Chen YS; Ma YN; Li PP; Yin XL Ann Hematol; 2018 Oct; 97(10):1933-1939. PubMed ID: 29931453 [TBL] [Abstract][Full Text] [Related]
20. Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia. Nisli G; Kavakli K; Aydinok Y; Oztop S; Cetingül N; Basak N Acta Haematol; 1997; 98(4):199-203. PubMed ID: 9401497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]